A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 13, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions

Healthy VolunteersHyperuricemia

Interventions

DRUG

NNC4004-0002

NNC4004-0002 will be given as a single ascending dose via subcutaneous route.

DRUG

Placebo

Placebo matched to NNC4004-0002 will be given via subcutaneous route.

Trial Locations (2)

RECRUITING

PAREXEL Intl - EPCU-Baltimore, Baltimore

NOT_YET_RECRUITING

PAREXEL Glendale/LA EPCU, Glendale